Osteoprotegerin Is Associated With Silent Coronary Artery Disease in High-Risk but Asymptomatic Type 2 Diabetic Patients

Pathophysiology/Complications

Address correspondence and reprint requests to Antoine Avignon, Metabolic Disease Department, Lapeyronie Hospital, 371, Av. Doyen G. Giraud, 34295, Montpellier, Cedex 5, France. E-mail: a-avignon{at}chu-montpellier.fr

Diabetes Care 2005 Sep; 28(9): 2176-2180. https://doi.org/10.2337/diacare.28.9.2176

Article Figures & Tables

Table 1—

Characteristics of the CAD and NO-CAD groups

	CAD	NO-CAD	P
n	20	20
Sex (men/women)	15/5	15/5	1.000
Age (years)	59.8 ± 9.5	60.9 ± 9.6	0.723
Duration of diabetes (years)	12.0 ± 6.6	10.5 ± 5.9	0.444
BMI (kg/m²)	29.8 ± 4.5	29.0 ± 3.6	0.543
A1C (%)	8.9 ± 2.7	8.3 ± 2.0	0.434
Left ventricular ejection fraction	56 ± 8	61 ± 9	0.059
Total cholesterol (mg/dl)	211 ± 39	198 ± 38	0.281
LDL cholesterol (mg/dl)	131 ± 37	104 ± 41	0.033
HDL cholesterol (mg/dl)	45 ± 8	58 ± 17	0.005
Triglycerides (mg/dl)	145 (59–395)	142 (72–390)
Subjects with triglycerides >150 mg/dl (%)	45.0	50.0	0.752
Nephropathy (%)	50.0	5.0	0.001
Retinopathy (%)	40.0	25.0	0.311
PAD (%)	20.0	0.0	0.035
Smokers (%)	35.0	20.0	0.288
Family history of CAD (%)	5.0	0.0	0.311
Hypertension (%)	95.0	85.0	0.282
Lp(a) (mg/dl)	13 (10–165)	21 (10–95)
Subjects with Lp(a) levels >30 mg/dl (%)	30.0	40	0.507
hs-CRP (mg/l)	3.30 (0.37–28.24)	1.92 (0.06–13.40)
Subjects with hs-CRP levels >median value (%)	60.0	35.0	0.113
Adiponectin (μg/ml)	7.17 (1.13–33.34)	11.55 (3.72–46.55)
Subjects with adiponectin levels <median value (%)	60.0	40.0	0.206
OPG (pmol/l)	13.97 (1.31–20.04)	9.44 (0.10–25.88)
Subjects with OPG levels >median value (%)	70.0	25.0	0.004